Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
about
Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients.Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
P2860
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Progression-free survival as s ...... tive metastatic breast cancer.
@en
Progression-free survival as s ...... tive metastatic breast cancer.
@nl
type
label
Progression-free survival as s ...... tive metastatic breast cancer.
@en
Progression-free survival as s ...... tive metastatic breast cancer.
@nl
prefLabel
Progression-free survival as s ...... tive metastatic breast cancer.
@en
Progression-free survival as s ...... tive metastatic breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Progression-free survival as s ...... tive metastatic breast cancer.
@en
P2093
G Gasparini
G von Minckwitz
J Barinoff
L Pugliano
P2860
P304
P356
10.1093/ANNONC/MDW132
P577
2016-03-08T00:00:00Z